Bactiguard
Bactiguard develops and provides infection prevention solutions that reduce the risk of healthcare-associated infections.
| SEK | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | (2 %) | 32 % | (9 %) | 28 % | - | 11 % | 14 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (4 %) | (1 %) | (38 %) | 10 % | 15 % | 20 % | 26 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (35 %) | (24 %) | (68 %) | (11 %) | (8 %) | 6 % | 14 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article, Equity research estimates
Related Content
Bactiguard is a medical technology company specializing in infection prevention solutions. The company operates in the healthcare sector, targeting hospitals and healthcare providers globally. Bactiguard's core products include advanced disinfectants, wound care solutions, and medical devices such as urinary catheters and central venous catheters that incorporate infection prevention technology. The company also collaborates with partners like Musti Group to expand its product range, including wound care for pets. Bactiguard generates revenue through the sale of its products and licensing agreements. The company is committed to contributing to global health goals by reducing hospital-acquired infections and antimicrobial resistance.
Keywords: infection prevention, patient safety, healthcare, medical devices, disinfectants, wound care, urinary catheters, antimicrobial resistance, global expansion, licensing agreements.
Tech stack
Investments by Bactiguard
Edit